FDA Commissioner Marty Makary announced a pilot program that will pay quarterly bonuses to drug reviewers who complete reviews ahead of schedule, according to slides and a staff presentation obtained by the Associated Press. The program ties payments to "weighted time savings," team contributions, and work‑quality ratings, and excludes staff not directly involved in reviews such as factory inspectors. Makary framed the payments as recognition for efficiency gains and said the pilot responds to staffing losses and workload pressures across the agency. Senior officials emphasized the program values speed without sacrificing quality, but the plan raises questions about metrics, team allocation and potential perceptions of rushed review. Regulatory affairs teams and drug developers should track implementation details—eligibility, measurement of time savings, and audit safeguards—because bonus incentives could shift reviewer behavior and timelines for regulatory interactions.